NCT00794261 - Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

June 30, 2010

Conditions

LymphomaMyeloma

Interventions

DRUG

Injection of Pegfilgrastim

Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5

DRUG

Injection of Filgrastim

Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN \> 0.5 G/L)

Trial Locations (11)

CHU Brest, Brest

CHU Toulouse - Hôpital Purpam, Toulouse

Hôpital Lapeyronnie, Montpellier

CHU Tours - Hôpital Bretonneau, Tours

CHU Nantes, Nantes

CHU Angers, Angers

Centre Leon Berard, Lyon

Hopital Edouard Herriot, Lyon

Centre Hospitalier Lyon Sud, Pierre-Bénite

Centre Henri Becquerel, Rouen

Institut Gustave Roussy, Villejuif